Digital health technologies and Alzheimer’s disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?

BACKGROUND: Therapeutic trials in Alzheimer’s disease (AD) face many obstacles—particularly with regard to screening and recruitment. DISCUSSION: Decentralized clinical trials (DCTs) are being developed in other diseases and appear to be of value for overcoming these difficulties. The use of remote...

Descripción completa

Detalles Bibliográficos
Autores principales: Leroy, Victoire, Gana, Wassim, Aïdoud, Amal, N’kodo, Jacques-Alexis, Balageas, Anna-Chloé, Blanc, Pascal, Bomia, Dominique, Debacq, Camille, Fougère, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133908/
https://www.ncbi.nlm.nih.gov/pubmed/37106429
http://dx.doi.org/10.1186/s13195-023-01227-4
_version_ 1785031658545610752
author Leroy, Victoire
Gana, Wassim
Aïdoud, Amal
N’kodo, Jacques-Alexis
Balageas, Anna-Chloé
Blanc, Pascal
Bomia, Dominique
Debacq, Camille
Fougère, Bertrand
author_facet Leroy, Victoire
Gana, Wassim
Aïdoud, Amal
N’kodo, Jacques-Alexis
Balageas, Anna-Chloé
Blanc, Pascal
Bomia, Dominique
Debacq, Camille
Fougère, Bertrand
author_sort Leroy, Victoire
collection PubMed
description BACKGROUND: Therapeutic trials in Alzheimer’s disease (AD) face many obstacles—particularly with regard to screening and recruitment. DISCUSSION: Decentralized clinical trials (DCTs) are being developed in other diseases and appear to be of value for overcoming these difficulties. The use of remote visits offers hope of broader recruitment and thus a reduction in inequalities due to age, geography, and ethnicity. Furthermore, it might be easier to involve primary care providers and caregivers in DCTs. However, further studies are needed to determine the feasibility of DCTs in AD. SUMMARY: A mixed-model DCT might constitute the first step towards completely remote trials in AD and should be assessed first.
format Online
Article
Text
id pubmed-10133908
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101339082023-04-28 Digital health technologies and Alzheimer’s disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment? Leroy, Victoire Gana, Wassim Aïdoud, Amal N’kodo, Jacques-Alexis Balageas, Anna-Chloé Blanc, Pascal Bomia, Dominique Debacq, Camille Fougère, Bertrand Alzheimers Res Ther Debate BACKGROUND: Therapeutic trials in Alzheimer’s disease (AD) face many obstacles—particularly with regard to screening and recruitment. DISCUSSION: Decentralized clinical trials (DCTs) are being developed in other diseases and appear to be of value for overcoming these difficulties. The use of remote visits offers hope of broader recruitment and thus a reduction in inequalities due to age, geography, and ethnicity. Furthermore, it might be easier to involve primary care providers and caregivers in DCTs. However, further studies are needed to determine the feasibility of DCTs in AD. SUMMARY: A mixed-model DCT might constitute the first step towards completely remote trials in AD and should be assessed first. BioMed Central 2023-04-27 /pmc/articles/PMC10133908/ /pubmed/37106429 http://dx.doi.org/10.1186/s13195-023-01227-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Debate
Leroy, Victoire
Gana, Wassim
Aïdoud, Amal
N’kodo, Jacques-Alexis
Balageas, Anna-Chloé
Blanc, Pascal
Bomia, Dominique
Debacq, Camille
Fougère, Bertrand
Digital health technologies and Alzheimer’s disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?
title Digital health technologies and Alzheimer’s disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?
title_full Digital health technologies and Alzheimer’s disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?
title_fullStr Digital health technologies and Alzheimer’s disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?
title_full_unstemmed Digital health technologies and Alzheimer’s disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?
title_short Digital health technologies and Alzheimer’s disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?
title_sort digital health technologies and alzheimer’s disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?
topic Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133908/
https://www.ncbi.nlm.nih.gov/pubmed/37106429
http://dx.doi.org/10.1186/s13195-023-01227-4
work_keys_str_mv AT leroyvictoire digitalhealthtechnologiesandalzheimersdiseaseclinicaltrialsmightdecentralizedclinicaltrialsincreaseparticipationbypeoplewithcognitiveimpairment
AT ganawassim digitalhealthtechnologiesandalzheimersdiseaseclinicaltrialsmightdecentralizedclinicaltrialsincreaseparticipationbypeoplewithcognitiveimpairment
AT aidoudamal digitalhealthtechnologiesandalzheimersdiseaseclinicaltrialsmightdecentralizedclinicaltrialsincreaseparticipationbypeoplewithcognitiveimpairment
AT nkodojacquesalexis digitalhealthtechnologiesandalzheimersdiseaseclinicaltrialsmightdecentralizedclinicaltrialsincreaseparticipationbypeoplewithcognitiveimpairment
AT balageasannachloe digitalhealthtechnologiesandalzheimersdiseaseclinicaltrialsmightdecentralizedclinicaltrialsincreaseparticipationbypeoplewithcognitiveimpairment
AT blancpascal digitalhealthtechnologiesandalzheimersdiseaseclinicaltrialsmightdecentralizedclinicaltrialsincreaseparticipationbypeoplewithcognitiveimpairment
AT bomiadominique digitalhealthtechnologiesandalzheimersdiseaseclinicaltrialsmightdecentralizedclinicaltrialsincreaseparticipationbypeoplewithcognitiveimpairment
AT debacqcamille digitalhealthtechnologiesandalzheimersdiseaseclinicaltrialsmightdecentralizedclinicaltrialsincreaseparticipationbypeoplewithcognitiveimpairment
AT fougerebertrand digitalhealthtechnologiesandalzheimersdiseaseclinicaltrialsmightdecentralizedclinicaltrialsincreaseparticipationbypeoplewithcognitiveimpairment

Ejemplares similares